Natco Pharma promoter group acquires shares via rights issue allotment
NiveshIQ
NSE: NATCOPHARM · Healthcare
NATCO Pharma Ltd.
₹785.75▲ ₹3.35 (+0.43%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on NATCOPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About NATCO Pharma Ltd.
NATCO Pharma Limited operates in pharmaceuticals and agrochemicals, manufacturing finished dosage forms, APIs, and intermediates across India, the US, and globally. The pharma segment focuses on oncology, CNS, pain, cardiovascular, orthopedics, gastroenterology, neurology, cardiology, and diabetology, while the agrochemicals arm is slated for a planned demerger, which has already spurred a 4% share rally. In FY26 the company reported a 25% decline in profit, yet FY27 revenue is projected at ₹3,400 crore, reflecting resilience in its core therapeutic areas. Recent approvals, such as the CDSCO clearance for semaglutide, have lifted the stock by 12% and attracted a $16.7 million eGenesis investment. A ₹2,000 crore fund‑raise proposal has been approved by shareholders to support expansion and
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,999 Cr +47.72% | ₹4,430 Cr +10.77% | ₹4,078 Cr -7.93% |
| EBITDA Margin | 43.80% | 49.58% | 35.22% |
| Net Profit | ₹1,388 Cr +94.09% | ₹1,885 Cr +35.81% | ₹1,418 Cr -24.76% |
| EPS | ₹77.34 | ₹105.26 | ₹79.20 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
NATCO Pharma Launches Carboplatin Injection in the US to Address Supply Shortage
NATCO Pharma Launches Generic Carboplatin Injection in the US
🔒
+ 3 more stories about NATCO Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹735 Cr, PAT ₹206 Cr, EPS ₹11.53, EBITDA margin 33.4%. Growth context: revenue QoQ -0.5%, PAT QoQ -23.2%. Street verdict: strong beat, revenue surprise -3.0%, PAT surprise +43.4%.
Management highlights product launches, approvals, and therapy‑mix improvement as the primary near‑term growth lever, wi...
FY26 (last completed FY): revenue ₹4, 078 Cr, PAT ₹1, 418 Cr, EBITDA margin 42.5%, EPS ₹79.20. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for NATCOPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track NATCOPHARM alongside your other holdings
Unlock full NATCOPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for NATCO Pharma Ltd.?
NiveshIQ detects active intelligence signals for NATCO Pharma Ltd. (NATCOPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for NATCO Pharma Ltd.?
NATCO Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,104,361.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.